Streetbeat News

SVRA

Savara Inc.

https://www.savarapharma.com

Industry

Biotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Open

3.35

Mkt cap

551M

Volume

3.2M

High

3.37

P/E Ratio

-7.83

52-wk high

5.70

Low

3.19

Div yield

N/A

52-wk low

2.81

Savara Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, a potential treatment for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI has received Fast Track and Breakthrough Therapy Designations.

Portfolio Pulse from

December 18, 2024 | 9:30 pm

Savara Inc. will present encore results from its Phase 3 IMPALA-2 trial of Molgramostim for treating autoimmune pulmonary alveolar proteinosis at the British Thoracic Society Winter Meeting 2024.

Portfolio Pulse from

November 22, 2024 | 1:15 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Savara (NASDAQ:SVRA) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 10:50 am

JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating for Savara (NASDAQ:SVRA) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:43 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Savara (NASDAQ:SVRA) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 11:01 am

Savara Inc. has launched an Expanded Access Program for its molgramostim inhalation solution, targeting patients with autoimmune pulmonary alveolar proteinosis (aPAP) in regions where the product is not yet commercially available. The program has received FDA approval and is currently accepting requests in select North American and European countries, with plans to expand through 2026.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 12:07 pm

JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating for Savara (NASDAQ:SVRA) and maintained a $9 price target.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 2:22 pm

Summit Therapeutics shares surged 38.8% in pre-market trading after announcing positive results for Ivonescimab Monotherapy in treating advanced NSCLC in China. Other notable pre-market movers include Intelligent Bio Solutions, Tonix Pharmaceuticals, and Nuburu, among others.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 10:08 am

Savara presented positive Phase 3 trial results for Molgramostim in treating autoimmune pulmonary alveolar proteinosis, showing significant improvements in disease severity and lung function compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:45 am

Savara announced the acceptance of an abstract for a poster presentation at the European Respiratory Society Congress 2024 in Vienna. The company will present results from the IMPALA-2 study on inhaled Molgramostim for autoimmune pulmonary alveolar proteinosis and sponsor an industry symposium.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:23 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.